Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/irinotecan-induced-transient-dysarthria-case-series-and-updated-2yTK8wBV3T
References (35)
-
D. Abigerges, G. Chabot, J. Armand, P. Hérait, A. Gouyette, D. Gandía (1995)
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 1
-
G. Masi, F. Loupakis, L. Salvatore, L. Fornaro, C. Cremolini, S. Cupini, A. Ciarlo, F. Monte, E. Cortesi, D. Amoroso, C. Granetto, G. Fontanini, E. Sensi, C. Lupi, M. Andreuccetti, A. Falcone (2010)
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.The Lancet. Oncology, 11 9
-
H. Dodds, L. Rivory (1999)
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).Molecular pharmacology, 56 6
-
D. Baz, J. Bofill, J. Nogueira (2001)
Irinotecan-induced dysarthria.Journal of the National Cancer Institute, 93 18
-
K. Gunturu, Xiaopan Yao, X. Cong, J. Thumar, H. Hochster, S. Stein, J. Lacy (2013)
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicityMedical Oncology, 30
-
L. Saltz, J. Cox, C. Blanke, L. Rosen, L. Fehrenbacher, M. Moore, J. Maroun, S. Ackland, P. Locker, N. Pirotta, G. Elfring, L. Miller (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.The New England journal of medicine, 343 13
-
M. Chandar, Robert Marsh (2015)
Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX ChemotherapyCase Reports in Oncology, 8
-
T. Okusaka, M. Ikeda, A. Fukutomi, T. Ioka, J. Furuse, S. Ohkawa, H. Isayama, N. Boku (2014)
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancerCancer Science, 105
-
B. Ceccaldi, F. Kara, H. Mommeja-Marin, M. Bégué, P. Blancard, E. Marec, D. Hauteville (2002)
Dysarthrie lors de l'administration d'irinotécanRevue de Médecine Interne, 23
-
M. Dank, J. Zaluski, C. Barone, V. Valvere, Ş. Yalçın, C. Peschel, M. Wenczl, E. Göker, L. Cisar, K. Wang, R. Bugat (2008)
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.Annals of oncology : official journal of the European Society for Medical Oncology, 19 8
-
B. Ceccaldi, F. Kara, H. Momméja-Marin, M. Bègue, P. Blancard, E. Marec, D. Hauteville (2002)
[Dysarthria during irinotecan administration].La Revue de medecine interne, 23 11
-
(2014)
Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancerOnco Targets Ther., 7
-
J. Douillard, D. Cunningham, A. Roth, M. Navarro, R. James, P. Karásek, P. Jandík, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, P. Rougier (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 355
-
I. García, A. Rueda, E. Alba (1999)
Irinotecan-induced central nervous system toxicity: a case report.Journal of the National Cancer Institute, 91 7
-
R. Joseph, C. Dasanu (2014)
A curious case of oxaliplatin-induced neurotoxicity: Recurrent, self-limiting dysarthriaJournal of Oncology Pharmacy Practice, 20
-
Jesus Gomez, I. Sánchez, J. Ramírez (2008)
Irinotecan-induced dysarthria: an insight into its pathogenesis?Gastrointestinal cancer research : GCR, 2 4
-
P. Hamberg, F. Jong, D. Brandsma, J. Verweij, S. Sleijfer (2008)
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literatureActa Oncologica, 47
-
S. Yomo, Tsuyoshi Tada, Shuichi Hirayama, Naoko Tachibana, Masako Otani, Yuichiro Tanaka, Kazuhiro Hongo (2006)
A case report and review of the literatureJournal of Neuro-Oncology, 81
-
E. Cutsem, C. Köhne, E. Hitre, J. Zaluski, Chung-Rong Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, G. Bodoky, J. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, P. Rougier (2009)
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.The New England journal of medicine, 360 14
-
Minmin Li, Zhehai Wang, Jun Guo, Jie Liu, Changzheng Li, Lin Liu, Huan Shi, Liyan Liu, Huihui Li, C. Xie, Xia Zhang, Wenwen Sun, S. Fang, X. Bi
Oncotargets and Therapy Dovepress Clinical Significance of Ugt1a1 Gene Polymorphisms on Irinotecan-based Regimens as the Treatment in Metastatic Colorectal Cancer -
J. Souglakos, N. Androulakis, K. Syrigos, A. Polyzos, N. Ziras, A. Athanasiadis, S. Kakolyris, S. Tsousis, C. Kouroussis, L. Vamvakas, A. Kalykaki, G. Samonis, D. Mavroudis, V. Georgoulias (2006)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)British Journal of Cancer, 94
-
A. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. Abubakr, M. Lutz, M. Vega-Villegas, C. Eng, E. Steinhauer, J. Prausová, H. Lenz, C. Borg, G. Middleton, H. Kröning, G. Luppi, O. Kisker, A. Zubel, C. Langer, J. Kopit, H. Burris (2008)
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
-
(2002)
Lettres à la rédactionDysarthrie lors de l’administration d’irinotécanDysarthria during irinotecan perfusion -
A. Dressel, J. Mijn, IJke Aalders, R. Rinkel, H. Vliet (2012)
Irinotecan-Induced DysarthriaCase Reports in Oncology, 5
-
(2008)
Irinotecan-induced dysarthria: an insight into its pathogenesis?Case Rep GI Oncol, 2
-
T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. Raoul, S. Gourgou-Bourgade, C. Fouchardière, J. Bennouna, J. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux (2011)
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.The New England journal of medicine, 364 19
-
Krista Ramirez, Marla Koch, W. Edenfield (2017)
Irinotecan-induced dysarthria: A case report and review of the literatureJournal of Oncology Pharmacy Practice, 23
-
M. Peeters, T. Price, A. Cervantes, A. Sobrero, M. Ducreux, Y. Hotko, T. André, E. Chan, F. Lordick, C. Punt, A. Strickland, G. Wilson, T. Ciuleanu, L. Roman, E. Cutsem, V. Tzekova, S. Collins, K. Oliner, A. Rong, J. Gansert (2010)
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 31
-
L. Wiseman, A. Markham (1996)
Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs, 52 4
-
A. Matsuoka, O. Maeda, M. Inada-Inoue, E. Ohno, Y. Hirooka, Y. Yokoyama, T. Fujii, M. Nagino, H. Goto, Y. Ando (2015)
FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases.Oncology letters, 10 4
-
C. Yoo, J. Hwang, June-sung Kim, Tark Kim, Jung-shin Lee, D. Park, S. Lee, D. Seo, S. Lee, Min-Seon Kim, D. Han, Song-Chul Kim, Jong-Keuk Lee (2009)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerBritish Journal of Cancer, 101
-
K. Lee, Hee Kang, J. Ahn, Hyoun Suk, Hyunah Kim (2013)
Dysarthria induced by irinotecan in a patient with colorectal cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 70 13
-
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 350 23
-
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crinò, G. Benedetti, W. Evangelista, L. Fanchini, E. Cortesi, V. Picone, S. Vitello, S. Chiara, C. Granetto, G. Porcile, L. Fioretto, C. Orlandini, M. Andreuccetti, G. Masi (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 13
-
S. Marco, E. Squilloni, L. Vigna, M. Bertagnolio, C. Sternberg (2004)
Irinotecan chemotherapy associated with transient dysarthria and aphasia.Annals of oncology : official journal of the European Society for Medical Oncology, 15 7
- Publisher
- Springer Journals
- Copyright
- Copyright © The Author(s) 2020
- Subject
- Medicine & Public Health; Internal Medicine
- ISSN
- 2366-1070
- eISSN
- 2366-1089
- DOI
- 10.1007/s40487-019-00106-z
- Publisher site
- See Article on Publisher Site
Abstract
Irinotecan-based regimens are used worldwide for the treatment of several recurrent or advanced gastrointestinal malignancies. In this paper we describe the cases of four patients treated in our institution who developed acute dysarthria while receiving intravenous infusion of irinotecan. In all our cases, dysarthria occurred during the infusion of the first course of irinotecan, and then resolved rapidly without any sequelae. Imaging of the brain was performed, but failed to show any evidence of an acute neurological event. We also reviewed the literature on this very uncommon adverse event. The pathogenesis of irinotecan-induced dysarthria is still unknown and is not completely elucidated by the current pharmacodynamic or kinetic explanations; therefore, we could only hypothesize some assumptions.
Journal
Oncology and Therapy – Springer Journals
Published: Jun 6, 2020